Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma
|
|
- Godwin Heath
- 6 years ago
- Views:
Transcription
1 Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma JULIA A. NIGHTINGALE, DUNCAN F. ROGERS, and PETER J. BARNES Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom Short-acting 2 -agonists provide greater protection against bronchoconstriction induced by adenosine 5 -monophosphate (AMP) than by direct-acting bronchoconstrictors such as histamine and methacholine. AMP is thought to cause bronchoconstriction via release of mediators from mast cells, which suggests that these drugs stabilize mast cells in vivo. This in vivo property has not yet been demonstrated for long-acting 2 -agonists. We undertook a double-blind, randomized, placebo-controlled, cross-over study to investigate the effects of a single dose of formoterol inhaled via Turbuhaler (12 g) and of albuterol inhaled via Turbuhaler (200 g) on airway responsiveness to AMP and histamine in 16 subjects with mild atopic asthma. Albuterol reduced airway responsiveness to AMP and histamine by and doubling doses, respectively. In contrast, formoterol caused a greater protective effect against AMP than against histamine challenge, decreasing airway responsiveness by and doubling doses, respectively (p 0.05). Thus, the long-acting 2 -agonist formoterol appears to have a mast cell-stabilizing effect in vivo in mild asthma. Nightingale JA, Rogers DF, Barnes PJ. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. AM J RESPIR CRIT CARE MED 1999;159: (Received in original form September 18, 1998 and in revised form December 14, 1998) Supported by a grant from Astra Draco AB (Lund, Sweden). Correspondence and requests for reprints should be addressed to Dr. J. A. Nightingale, Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK. Am J Respir Crit Care Med Vol 159. pp , 1999 Internet address: Inhaled 2 -adrenoceptor agonists are the most effective bronchodilators available for the treatment of acute symptoms in asthma (1). The introduction of the long-acting 2 -agonists salmeterol and formoterol allowed these drugs to be prescribed as regular treatment in subjects who continue to be symptomatic despite the use of inhaled corticosteroids (2). In addition to their bronchodilator effects, inhaled 2 -agonists also protect against a variety of direct and indirect bronchoconstrictor stimuli (3 6). Short-acting 2 -agonists provide greater bronchoprotection against the indirect stimulator adenosine 5 -monophosphate (AMP) than against direct airway smooth muscle stimulators, such as methacholine or histamine, in subjects with mild asthma (4, 7). Because AMP stimulates the release of histamine and other preformed spasmogens from mast cells (8, 9), the differential bronchoprotection by 2 - agonists has been interpreted as mast cell stabilization. However, this differential bronchoprotective effect was not seen with salmeterol at either 2 h (10) or 14 h after a single dose (11). This lack of mast cell-stabilizing effect of salmeterol may reflect the fact that it is a partial agonist compared with albuterol or terbutaline. We hypothesized that formoterol, which is a virtually full agonist, should have a greater protective effect on mast cell mediator release than the partial agonist salmeterol. We investigated the mast cell-stabilizing effects of formoterol 30 min after a single dose in subjects with mild asthma. We hypothesized that formoterol would provide greater protection against the mast cell stimulus AMP than against a direct challenge with histamine. We also studied the protective effect against AMP or histamine of a single dose of albuterol (given via the same inhaler device) as a control. METHODS Subjects Sixteen nonsmoking subjects meeting the American Thoracic Society criteria for asthma (12) (9 females and 7 males; mean age, yr; Table 1) took part. All had mild asthma (FEV 1 70% predicted), and a positive skin prick test to common aeroallergens (Dermatophagoides pteronyssinus, grass pollen, Aspergillus fumigatus, or cat). Subjects demonstrated sensitivity to inhaled histamine (PC 20 [provocative concentration of histamine or AMP causing a 20% drop in FEV 1 ] 1 mg/ml) and AMP (PC mg/ml) in the 2 wk before entry. None had an exacerbation of asthma or an upper respiratory tract infection in the previous 6 wk. Subjects were steroid free for at least 2 mo before entry and took no regular treatment for their asthma other than intermittent short-acting 2 -agonists. Written informed consent was obtained from each subject and the study was approved by the Ethics Committee of the Royal Brompton Hospital and the National Heart and Lung Institute (London, UK). Study Protocol The trial was double-blind, placebo-controlled, randomized, and crossover. Subjects attended two screening visits to determine bronchial reactivity to AMP and histamine. At the initial screening visit subjects were converted to ipratropium bromide as a rescue inhaler for the duration of the study. After screening, subjects attended for six treatment visits with an identical protocol: baseline spirometry was followed by drug administration. Subjects inhaled either 12 g of formoterol by Turbuhaler (Astra Draco AB, Lund, Sweden) (2 6 g) plus two puffs of placebo, or 200 g of albuterol by Turbuhaler (2 100 g) plus two puffs of placebo or two matched placebo inhalers (two puffs of each). Thirty minutes later, spirometry was performed again and the subject was challenged with either histamine or AMP.
2 Nightingale, Rogers, and Barnes: Formoterol and Airway Reactivity 1787 The sequence of challenges was randomized such that one challenge agent was administered on the first three visits and the other on the final three visits. A washout period (minimum, 72 h; maximum, 2 wk) separated each visit. Subjects were asked to refrain from taking rescue medication or caffeinated beverages for at least 12 h before each visit and attended at a similar time of day for each visit. Histamine and AMP Challenges Solutions of histamine and AMP (Sigma, Poole, UK) were made up immediately before challenge in 0.9% saline in concentrations of mg/ml for histamine and of mg/ml for AMP. For AMP, the 800-mg/ml dose was kept at 30 C to keep the AMP in solution. Doses were inhaled via a nebulizer attached to a breath-activated dosimeter (Mefar, Brescia, Italy), which delivered particles with an aerodynamic mass median diameter of m at an output of 9 l per breath. A standard procedure was used for all provocation tests. Baseline FEV 1 was measured using a dry wedge spirometer (Vitalograph, Buckingham, UK). Three values of FEV 1 were recorded at 1-min intervals and the best taken as baseline. Subjects inhaled five breaths of normal saline as a control, each breath taking 1 s with a 6-s breath-hold. FEV 1 was measured 2 min later. The subject then inhaled a series of doubling concentrations of histamine or AMP, starting with the lowest dose, at 3-min intervals with FEV 1 measured 2 min after each dose. Challenges were terminated when the FEV 1 fell by 20% from the post-saline value or the top dose was reached. A log dose response curve was constructed and the concentration causing a 20% fall in FEV 1 from the post-saline value (PC 20 ) was calculated by linear interpolation and expressed in noncumulative units. If a subject did not respond to the highest concentration, a linear extrapolation was made using the final two doses. If this extrapolation gave a value between the highest concentration and double the highest concentration, the extrapolated value was used for analysis. If the value was greater than the highest concentration doubled, the highest concentration doubled was used. Subject Age (yr) TABLE 1 SUBJECT CHARACTERISTICS Sex FEV 1 (% pred ) Atopy Screening PC 20 Histamine AMP 1 33 M 81.2 C, G, H M 90.7 C, H, G, A F 91.3 G, H, C, A M 84.1 C, H, G, A F 88.5 C, H, G F 86.6 H, C, G, A F 92.8 H, C, G F 84.5 H, C, G, A M H, C F 80.8 C, G, H M C, G, H, A F C, G F G, C, H M 84.4 H, G F 72.8 C, H, A M 92.4 C, H, G Mean Definition of abbreviations: A Aspergillus fumigatus; AMP adenosine monophosphate; C cat; G grass pollen; H house dust mite; HA histamine; % pred FEV 1 expressed as a percentage of the predicted value; PC 20 provocative concentration of histamine or AMP causing a 20% drop in FEV 1 (in mg/ml). Data Analysis Results are presented as means 1 standard error of the mean (SEM) unless otherwise stated. PC 20 values were log-transformed for analysis and geometric means calculated. The protective effect of formoterol or albuterol against AMP or histamine was calculated by comparing in each subject the difference in PC 20 after inhaling the respective active treatment with that achieved after inhaling placebo. The effect is expressed as doubling doses, using the formula: To determine the validity of comparing the effects of the drugs on different challenges, dose response curves were constructed for each spasmogen after each treatment. FEV 1 values after inhalation of the final four concentrations of spasmogen were calculated as a percentage of the post-saline value and compared by multifactorial analysis of variance (ANOVA). Values were included in this analysis only if a 20% fall in FEV 1 was achieved. Serial measurements within groups (baseline FEV 1, change from baseline FEV 1 with treatment) were analyzed by repeated measures ANOVA, followed by pairwise comparisons using the Bonferroni correction (13). Paired data (log PC 20 values, doubling dose changes in log PC 20 ) and unpaired data between groups (screening data, doubling dose changes in log PC 20 ) were compared using the appropriate two-tailed t test. Statistical significance was taken as p RESULTS ( log 10 PC 20 active treatment log 10 PC 20 placebo) log 10 2 Bronchodilator Effect Baseline FEV 1 values did not differ between screening visits or any of the six study visits (AMP challenges: placebo, ; formoterol, ; albuterol, ; histamine challenges: placebo, ; formoterol, ; albuterol, ). Both formoterol and albuterol caused significant increases in FEV 1 before AMP and histamine challenge (Figure 1). There was no significant difference in the size of the bronchodilator response to inhaled formoterol or albuterol (Figure 1). Bronchoprotective Effect After formoterol treatment, the geometric mean PC 20 for AMP was mg/ml, compared with 4.3 mg/ml after placebo (p ), and after albuterol it was 72.4 mg/ml (p versus placebo) (Table 2). The geometric mean PC 20 for histamine after formoterol treatment was 6.8 mg/ml, compared with 0.4 mg/ml after placebo (p ), and 4.1 mg/ml after albuterol (p versus placebo) (Table 2). One subject reached the top dose during histamine challenge after both formoterol and albuterol treatment. The top dose of AMP was reached in seven subjects after formoterol treatment and in three subjects after albuterol treatment. The protective effect of albuterol against AMP and histamine did not differ significantly: and doubling doses, respectively (Figure 2). However, the protective effect of formoterol was Figure 1. Bronchodilator response 30 min after inhalation of placebo (open bars), 12 g of formoterol (closed bars), or 200 g of albuterol (hatched bars). Values shown represent the increase in forced expiratory volume in 1 s (FEV 1 ) in liters before challenge with adenosine 5 -monophosphate (AMP) or histamine. Data are means and 1 SEM for 16 subjects. ***p versus placebo; NS nonsignificant.
3 1788 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL significantly greater against AMP ( doubling doses) than against histamine ( doubling doses, p 0.05) (Figure 2). The dose response curves to AMP and histamine were similar in shape after placebo treatment and were not significantly altered by either formoterol or albuterol treatment (Figure 3). DISCUSSION TABLE 2 EFFECT OF ALBUTEROL (200 g) AND FORMOTEROL (12 g) ON AIRWAY RESPONSIVENESS TO AMP OR HISTAMINE* Figure 2. The protective effect of formoterol (12 g) or albuterol (200 g) on airway responsiveness to adenosine 5 -monophosphate (AMP) (closed bars) or histamine (open bars) determined at 30 min. Data are means and 1 SEM for n 16 subjects. *p The present study has shown that a single dose of inhaled formoterol reduced airway responsiveness to histamine by 4.2 doubling doses but caused a greater reduction in airway responsiveness to AMP (6.0 doubling doses). In contrast, a single dose of inhaled albuterol decreased airway responsiveness to AMP and histamine to a similar extent (4.1 and 3.5 doubling doses, respectively). This greater protective effect of formoterol against AMP suggests a mast cell-stabilizing effect for formoterol. The greater protective effect of formoterol against AMP compared with histamine cannot be explained by functional antagonism alone, and may be due to nonsmooth muscle activity. AMP indirectly stimulates bronchoconstriction in asthma, and is thought to activate airway mast cells to release bronchospastic mediators, including histamine (14, 15). 2 -Agonists inhibit release of histamine from human mast cells in vitro, an effect demonstrated for both albuterol (16 18) and long-acting 2 -agonists salmeterol and formoterol (17, 18). Albuterol also inhibits the increase in plasma histamine after allergen challenge in vivo (19), an action likely to be mediated by mast cells. These findings suggest that the greater protective effect of 2 -agonists against AMP is due to a protective effect on airway mast cells. We included in the analysis extrapolated PC 20 data on seven subjects in whom we were unable to calculate a true PC 20 value after treatment because of profound bronchoprotection (three with AMP and one with histamine after albuterol; seven with AMP and one with histamine after formoterol). These data may lead to an underestimation of the protective effect of the drugs, or to an overestimation of the effect if the dose response curve to the next dose suddenly steepens. Overestimation is unlikely to account for the differential protective effect of formoterol against AMP compared with histamine seen in the present study. For the seven subjects who reached the top dose of AMP after formoterol treatment, all estimates lay on the flat part of the dose response curve (FEV 1 values of , , , and L/min, respectively, after the final four doses of AMP challenge). Previous studies have demonstrated an increased bronchoprotective effect against AMP compared with histamine for both albuterol (4, 10) and terbutaline (7), suggesting that both drugs have mast cell-stabilizing properties. In contrast, in the present study, although the protective effect of albuterol was greater against AMP than against histamine (4.1 and 3.5 doubling doses, respectively), the difference was not significant. A possible explanation for the lack of difference is our inclusion of data on subjects demonstrating profound bronchoprotection after albuterol inhalation (two with AMP and one with both AMP and histamine). As discussed above, this may underestimate the protective effect of AMP to a greater extent than that of histamine. In support of this argument, the present study found a protective effect against histamine (3.5 doubling doses) similar to that reported previously (3.3 [4] and 3.8 [10] doubling doses). However, there was less protection against AMP (4.1 doubling doses) than in the latter two studies (4.7 and 5.1 doubling doses). AMP Histamine Subject Placebo Formoterol Albuterol Placebo Formoterol Albuterol , , , , , , , , , , Mean * Values are given as the concentration of spasmogen required to cause a 20% fall in FEV 1. All values are expressed as milligrams per milliliter. Figure 3. Dose response curves for bronchial provocation challenge after inhalation of placebo, formoterol (12 g), or albuterol (200 g). Forced expiratory volume in 1 s (FEV 1 ) values are expressed as a percentage of the post-saline value obtained after inhaling the final four doubling increments of AMP (A) or histamine (B) required to reach a 20% fall in FEV 1 from the post-saline value (PC 20 ). X denotes the final concentration, X/2 the penultimate concentration, and so on.
4 Nightingale, Rogers, and Barnes: Formoterol and Airway Reactivity 1789 Second, a lower dose of albuterol (200 g) was used herein, compared with 400 g (10) and 2.5 mg (4) in previous studies. Although 200 g of albuterol via Turbuhaler is comparable to 400 g via Diskhaler in terms of bronchodilator effect (20), their bronchoprotective effects may not be comparable. The mast cell-stabilizing effect of albuterol in vitro is dose dependent, with albuterol being approximately 100 times less potent than formoterol (17). The protective effect of terbutaline against AMP in patients with asthma is also dose dependent (3). The dose of albuterol used in the present study may be too low for a mast cell effect to be demonstrated. Finally, the short duration of action of albuterol may have contributed to its weaker protective effect compared with formoterol. The maximum possible time between inhalation of 2 - agonist and end of provocation challenge was 69 min (30 min before the start of challenge plus up to 39 min to administer all doses of spasmogen). However, the maximal bronchodilator effect of albuterol is maintained for at least 90 min (21). Consequently, loss of efficacy of albuterol over the time taken to achieve a response is unlikely to account for the weaker protective effect of albuterol compared with formoterol. A comparison of the change in dose response with different challenges is valid only if the dose response to each challenge is similar, a unit shift in the dose response curve for one stimulus being equivalent to the unit shift for another stimulus. To assess this, we compared dose response curves after the final four doses of each spasmogen and found no differences with placebo or active treatments. Thus, both formoterol and albuterol caused parallel shifts in the AMP and histamine dose response curves, confirming the validity of comparisons between AMP and histamine challenges in the present study. We did not include data from subjects in whom a PC 20 had not been achieved at the final dose of spasmogen, because they had not reached an equivalent part of the dose response curve. Because the end point of the study was PC 20, we had insufficient points to calculate the true slope of the dose response curves. Although we did not observe any steepening of the dose response curve for either spasmogen after albuterol and formoterol treatment, it is possible this may become apparent with greater bronchoconstriction (22, 23). Although mast cell stabilization has previously been demonstrated in vivo for short-acting 2 -agonists, this is the first study to demonstrate this effect with a long-acting 2 -agonist. Salmeterol has no in vivo mast cell-stabilizing properties either 2 h (10) or 14 h (11) after inhalation. A possible explanation for the lack of effect of salmeterol compared with formoterol is the time point studied. Protection in the present study was measured at 30 min rather than later, at 2 or 14 h (10, 11), which may allow time for receptor desensitization. However, desensitization after a single dose of salmeterol is unlikely to be apparent as early as 2 h after dosing. Another possibility is the partial agonist nature of salmeterol (24). In guinea pig eosinophils, formoterol inhibits release of mediators, whereas salmeterol not only is ineffective but also blocks the action of formoterol (25). It is not reported whether a similar phenomenon exists for human lung mast cells. In conclusion, our results demonstrate that a single dose of formoterol not only causes inhibition of nonspecific bronchoconstriction but may have an additional inhibitory effect on bronchoconstrictor stimuli that involve mast cell activation. Thus, it may be that inhaled formoterol has an additional protective effect against stimuli thought to involve mast cell degranulation, such as exercise and allergen, in addition to that due to functional antagonism alone. Whether these beneficial actions of formoterol persist after prolonged therapy requires further study. Acknowledgment : The authors thank Astra Draco (Lund, Sweden) for support and supply of the drugs, and Mrs. S. Meah and Ms. C. Kelly for technical assistance. References 1. Nelson, H. S Adrenergic bronchodilators. N. Engl. J. Med. 333: British Thoracic Society Asthma in adults and schoolchildren. Thorax 52(Suppl. 1):S2 S8. 3. O Connor, B. J., R. W. Fuller, and P. J. Barnes Nonbronchodilator effects of inhaled 2 agonists: greater protection against adenosine monophosphate- than methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 150: Phillips, G. D., J. P. Finnerty, and S. T. Holgate Comparative protective effect of the inhaled 2 -agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5 -monophosphate in asthma. J. Allergy Clin. Immunol. 85: Rabe, K. F., R. Jorres, D. Nowak, N. Behr, and H. Magnussen Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am. Rev. Respir. Dis. 147: Palmqvist, M., B. Balder, O. Löwhagen, B. Melander, N. Svedmyr, and L. Wåhlander Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting 2 -agonist. J. Allergy Clin. Immunol. 89: O Connor, B. J., S. L. Aikman, and P. J. Barnes Tolerance to the nonbronchodilator effects of inhaled 2 -agonists in asthma. N. Engl. J. Med. 327: Cushley, M. J., and S. T. Holgate Adenosine-induced bronchoconstriction in asthma: role of mast cell-mediator release. J. Allergy Clin. Immunol. 75: Björck, T., L. E. Gustafsson, and S. E. Dahlén Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am. Rev. Respir. Dis. 145: Taylor, D. A., M. W. Jensen, S. L. Aikman, J. G. Harris, P. J. Barnes, and B. J. O Connor Comparison of salmeterol and albuterolinduced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am. J. Respir. Crit. Care Med. 156: Solèr, M., L. Joos, C. T. Bolliger, S. Elsasser, and A. P. Perruchoud Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine and AMP-induced bronchoconstriction. Eur. Respir. J. 7: American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am. Rev. Respir. Dis. 136: Glantz, S. A Primer of Biostatistics, 4th ed. McGraw-Hill, New York. 14. Phillips, G. D., P. Rafferty, R. Beasley, and S. T. Holgate Effect of oral terfenadine on the bronchoconstrictor response to inhaled histamine and adenosine 5 -monophosphate in non-atopic asthma. Thorax 42: Rafferty, P., R. Beasley, and S. T. Holgate The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5 -monophosphate in atopic asthma. Am. Rev. Respir. Dis. 136: Church, M. K., and J. Hiroi Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br. J. Pharmacol. 90: Lau, H. Y., P. L. Wong, C. K. Lai, and J. K. Ho Effects of long-acting beta 2-adrenoceptor agonists on mast cells of rat, guinea pig, and human. Int. Arch. Allergy Immunol. 105: Nials, A. T., D. I. Ball, P. R. Butchers, R. A. Coleman, A. A. Humbles, M. Johnson, and C. J. Vardey Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur. J. Pharmacol. 251: Howarth, P. H., S. R. Durham, T. H. Lee, A. B. Kay, M. K. Church, and S. T. Holgate Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am. Rev. Respir. Dis. 132: Carlsson, L.-G., E. Arweström, K. Friberg, C. G. Löfdahl, and H. Lunde Efficacy of cumulative doses of salbutamol administered via Turbuhaler or Diskhaler in patients with reversible obstruction. Allergy 53: Ruffin, R. E., J. D. Fitzgerald, and A. S. Rebuck A comparison of
5 1790 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL the bronchodilator activity of Sch 1000 and salbutamol. J. Allergy Clin. Immunol. 59: Bel, E. H., A. H. Zwinderman, M. C. Timmers, J. H. Dijkman, and P. J. Sterk The protective effect of a 2 -agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 46: Wong, A. G., A. D. O Shaughnessy, C. M. Walker, and M. R. Sears Effects of long-acting and short-acting -agonists on methacholine dose-response curves in asthmatics. Eur. Respir. J. 10: Jeppsson, A.-B., B.-L. Källström, and B. Waldeck Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro. Pharmacol. Toxicol. 71: Rabe, K. F., M. A. Giembycz, R. S. Perkins, P. Evans, and P. J. Barnes Salmeterol is a competetive antagonist at beta-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur. J. Pharmacol. 231:
NON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS. J. Sastre. Allergy Service
NON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS J. Sastre. Allergy Service Asthma: definition Asthma is a syndrome defined on basis of three main aspects: 1- Symptoms due to variable and reversible airway obstruction
More informationTolerance to beta-agonists during acute bronchoconstriction
Eur Respir J 1999; 14: 283±287 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Tolerance to beta-agonists during acute bronchoconstriction
More informationEffect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Eur Respir J 2001; 17: 374 379 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Effect of oral prednisolone on the bronchoprotective effect
More informationAdenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma
Respiratory Medicine (2004) 98, 651 655 Adenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma E. Bucchioni, Z. Csoma, L. Allegra, K.F. Chung, P.J. Barnes, S.A. Kharitonov*
More informationEffect of short- and long-acting inhaled β 2 -agonists on exhaled nitric oxide in asthmatic patients
Eur Respir J 1997; 10: 1483 1488 DOI: 10.1183/09031936.97.71483 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Effect of short- and long-acting
More informationBronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness
ORIGINAL ARTICLE Bronchodilator Response in Patients with Persistent Allergic Asthma Could Not Predict Airway Hyperresponsiveness Bojana B. Petanjek, MD, Sanja P. Grle, MD, Dubravka Pelicarić, MD, and
More informationSalmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients
Thorax 1988;43:674-678 Salmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients ANDERS ULLMAN, NILS SVEDMYR From the Department of Clinical
More informationTolerance to bronchodilating effects of salmeterol in COPD
Respiratory Medicine (2003) 97, 1014 1020 Tolerance to bronchodilating effects of salmeterol in COPD J.F. Donohue a, *, S. Menjoge b, S. Kesten b a University of North Carolina School of Medicine, 130
More informationLeukotriene C 4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Publishing 2003? 2003564422426Original ArticleLeukotriene C4 synthasej. J. Lima et al. Leukotriene C 4 synthase
More informationBeta 2 adrenoceptor agonists and the Olympic Games in Athens
Beta 2 adrenoceptor agonists and the Olympic Games in Athens 1 Appendix A of the Olympic Movement Anti-Doping Code, the List of Prohibited Substances and Prohibited Methods dated 1 st January 2003 states
More informationThe New England Journal of Medicine
A COMPARISON OF LOW-DOSE INHALED BUDESONIDE PLUS THEOPHYLLINE AND HIGH-DOSE INHALED BUDESONIDE FOR MODERATE ASTHMA DAVID J. EVANS, M.B., DAVID A. TAYLOR, M.B., OLLE ZETTERSTROM, M.D., K. FAN CHUNG, M.D.,
More informationYoung Yoo, MD; Jinho Yu, MD; Do Kyun Kim, MD; and Young Yull Koh, MD
Original Research ASTHMA Percentage Fall in FVC at the Provocative Concentration of Methacholine Causing a 20% Fall in FEV 1 in Symptomatic Asthma and Clinical Remission During Adolescence* Young Yoo,
More informationMechanisms of action of bronchial provocation testing
Mechanisms of action of bronchial provocation testing TSANZ / ANZSRS Masterclass: April 3rd, 2016 13:00 13:30 John D. Brannan PhD Scientific Director - Dept. Respiratory & Sleep Medicine John Hunter Hospital,
More informationEffects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma
Effects of Terbutaline and Budesonide on Sputum Cells and Bronchial Hyperresponsiveness In Asthma RUTH E. ALDRIDGE, ROBERT J. HANCOX, D. ROBIN TAYLOR, JAN O. COWAN, MARTI C. WINN, CHRIS M. FRAMPTON, and
More informationBorg scores before and after challenge with adenosine 5'-monophosphate and methacholine in subjects with COPD and asthma
Eur Respir J 2000; 16: 486±490 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Borg scores before and after challenge with adenosine 5'-monophosphate
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationSalmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action
Eur Respir J, 1996, 9, 1684 1688 DOI:.1183/09031936.96.09081684 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1996 European Respiratory Journal ISSN 0903-1936 Salmeterol versus formoterol
More informationTime course of action of two inhaled corticosteroids, fluticasone propionate and budesonide
ASTHMA Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide K Phillips, J Oborne, S Lewis, T W Harrison, A E Tattersfield... See end of article for authors affiliations...
More informationThe influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm
European Review for Medical and Pharmacological Sciences 2005; 9: 117-123 The influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm B. SPOSATO 1,2, S. MARIOTTA 1,2,
More informationRespiratory Pharmacology PCTH 400 Asthma and β-agonists
Respiratory Pharmacology PCTH 400 Asthma and β-agonists Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Director, Centre of
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationCorrespondence: C-G. Löfdahl Dept of Respiratory Medicine and Allergology University Hospital S Lund Sweden.
Eur Respir J 1997; 10: 2474 2478 DOI: 10.1183/09031936.97.10112474 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Differences in bronchodilating
More informationT he development of tolerance following the use of long
662 ASTHMA Cross tolerance to salbutamol occurs independently of b 2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol D K C Lee, C M Jackson, C E Bates, B J Lipworth...
More informationAirway calibre as a confounder in interpreting
702 Medical Department TTA 7511, State University Hospital, Copenhagen, Denmark A Dirksen F Madsen T Engel L Frolund J H Heing H Mosbech Reprint requests to: Dr A Dirksen, Department of Pulmonary Medicine
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationN. Crimi, R. Polosa, S. Magrì, G. Prosperini, V.L. Milazzo, G. Santonocito, A. Mistretta
Eur Respir J, 1995, 8, 5 912 DOI: 10.1183/031936.95.05 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 03-1936 Inhaled lysine acetylsalicylate (L-ASA)
More informationBenzalkonium Chloride Induced Bronchoconstriction in Patients with Stable Bronchial Asthma
The Korean Journal of Internal Medicine : 22:244-248, 2007 Benzalkonium Chloride Induced Bronchoconstriction in Patients with Stable Bronchial Asthma Byoung Hoon Lee, M.D. and Sang-Hoon Kim, M.D. Department
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationLack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma
Lack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma HAROLD S. NELSON, ROBERT B. BERKOWITZ, DAVID A. TINKELMAN, AMANDA H. EMMETT, KATHLEEN A. RICKARD, and STEVEN
More informationExercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute
Exercise-Induced Bronchospasm Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute EIB Episodic bronchoconstriction with exercise May be an exacerbation
More informationC.M.E. Tranfa, A. Vatrella, R. Parrella, F. Bariffi
Eur Respir J, 1995, 8, 6 64 DOI: 1.1183/931936.95.846 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 93-1936 Effect of ipratropium bromide and/or
More informationChallenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products
Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products Tushar Shah, M.D. Sr. VP, Global Respiratory Research and Development TEVA Pharmaceuticals 1 Presentation
More informationBronchial hyperresponsiveness in asthmatic adults A long-term correlation study
European Review for Medical and Pharmacological Sciences 2005; 9: 125-131 Bronchial hyperresponsiveness in asthmatic adults A long-term correlation study R. CARBONE, F. LUPPI *, A. MONSELISE **, G. BOTTINO
More informationRole of bronchoprovocation tests in identifying exercise-induced bronchoconstriction in a non-athletic population: a pilot study
Original Article Role of bronchoprovocation tests in identifying exercise-induced bronchoconstriction in a non-athletic population: a pilot study Jessica H. Y. Tan 1 *, Wui Mei Chew 1 *, Therese S. Lapperre
More informationRepeated Aerosol Exposure to Small Doses of Allergen A Model for Chronic Allergic Asthma
Repeated Aerosol Exposure to Small Doses of Allergen A Model for Chronic Allergic Asthma S. HASAN ARSHAD, ROBERT G. HAMILTON, and N. FRANKLIN ADKINSON, Jr. Department of Medicine, Division of Allergy and
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationReversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Eur Respir J 2001; 17: 368 373 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Reversing acute bronchoconstriction in asthma: the effect of
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 120 No 1267 ISSN 1175 8716 Is Salamol less effective than Ventolin? A randomised, blinded, crossover study in New Zealand Catherina L Chang, Manisha Cooray, Graham Mills,
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationThe effect of caffeinated coffee on airway response to methacholine and exhaled nitric oxide
Respiratory Medicine (2011) xx, 1e5 + MODEL available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed The effect of caffeinated coffee on airway response to methacholine and exhaled
More informationInfluence of Beclomethasone and Salmeterol on the Perception of Methacholine-Induced Bronchoconstriction*
Influence of Beclomethasone and Salmeterol on the Perception of Methacholine-Induced Bronchoconstriction* Louis-Philippe Boulet, MD, FCCP; Helene Turcotte, MS; Andre Cartier, MD; Joanne Milot, BS; Johanne
More informationResponse to inhaled albuterol during nocturnal asthma
Response to inhaled albuterol during nocturnal asthma Leslie Hendeles, PharmD, a Russell Beaty, MD, d Richard Ahrens, MD, e Gary Stevens, PhD, b and Eloise M. Harman, MD c Gainesville, Fla, Birmingham,
More informationRespiratory Pharmacology
Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationAn inhaled steroid improves markers of airway inflammation in patients with mild asthma
Eur Respir J 998; : 8 88 DOI:.8/996.98.8 Printed in UK - all rights reserved Copyright ERS Journals Ltd 998 European Respiratory Journal ISSN 9-96 An inhaled steroid improves markers of airway inflammation
More informationEmily DiMango, MD Asthma II
Emily DiMango, MD Asthma II Director John Edsall/John Wood Asthma Center Columbia University Medical Center HP 2000 Goal: 2.25/1,000 Comparison of Asthma Hospitalization Rates in Children Aged 0-14 in
More informationAsthma Pathophysiology and Treatment. John R. Holcomb, M.D.
Asthma Pathophysiology and Treatment John R. Holcomb, M.D. Objectives Definition of Asthma Epidemiology and risk factors of Asthma Pathophysiology of Asthma Diagnostics test of Asthma Management of Asthma
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationPerforming a Methacholine Challenge Test
powder for solution, for inhalation Performing a Methacholine Challenge Test Provocholine is a registered trademark of Methapharm Inc. Copyright Methapharm Inc. 2016. All rights reserved. Healthcare professionals
More informationIncreased Releasability of Skin Mast Cells after Exercise in Patients with Exercise-induced Asthma
J Korean Med Sci 4; 19: 724-8 ISSN 11-8934 Copyright The Korean Academy of Medical Sciences Increased Releasability of Skin Mast Cells after Exercise in Patients with Exercise-induced Asthma The role of
More informationInhibition of sodium metabisulphite induced bronchoconstriction by frusemide in asthma:
Thorax 1994;49:307-311 Department of Thoracic Medicine, National Heart and Lung Institute, Royal Brompton National Heart and Lung Hospitals, London SW3 6LY B J O'Connor P J Barnes K Fan Chung Reprint requests
More informationbronchoconstriction Inhaled antihistamines- bronchodilatation and effects on histamine- and methacholine-induced Thorax, 1978, 33,
Thorax, 1978, 33, 700-704 Inhaled antihistamines- bronchodilatation and effects on histamine- and methacholine-induced bronchoconstriction S G NOGRADY AND C BEVAN From the Welsh National School of Medicine
More informationAsthma in the Athlete
Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationSergio Bonini. Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy.
Assessment of EIA in the community and in athletes: the role of standardized questionnaires Sergio Bonini Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy se.bonini@gmail.com
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationCharacterisation of bronchoconstrictor responses to sodium metabisulphite aerosol in atopic subjects with and without asthma
Thorax 1989;44:19-114 Characterisation of bronchoconstrictor responses to sodium metabisulphite aerosol in atopic subjects with and without asthma G M NICHOL, A NIX, K F CHUNG, P J BARNES From the Department
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationAsthma. chapter 7. Overview
chapter 7 Asthma Sinus Sinus Sinus Right lung Adenoids Tonsils Pharynx Epiglottis Oesophagus Right bronchus Nasal cavity Oral cavity Tongue Larynx Trachea Ribs Left bronchus Diaphragm Bronchiole Pleura
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationRespiratory Health L O O K, F E E L A N D L I V E B E T T E R
LOOK, FEEL AND LIVE BET TER Respiratory health: hay-fever and asthma Airway obstruction and symptoms in asthma and hay-fever alike are the result of inappropriate responses of the body s immune system
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationDeterminants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction
Respiratory Medicine (2006) 100, 1760 1766 Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction Heikki O. Koskela a,, Vesa Kiviniemi b, Minna K. Purokivi
More informationC linicians have long regarded asthma as a heterogeneous
875 ORIGINAL ARTICLE Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids R H Green, C E Brightling,
More informationBronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013
Bronchial asthma E. Cserháti 1 st Department of Paediatrics Lecture for english speaking students 5 February 2013 Epidemiology of childhood bronchial asthma Worldwide prevalence of 7-8 and 13-14 years
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationProtective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine In asthma
Eur Aesplr J 1992, 5, 56()-665 Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine In asthma N. Crimi, F. Palermo, R. Oliveri, R. Polosa, I. Settinieri,
More informationAsthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.
Asthma Asthma Description Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Symptoms of asthma In susceptible individuals, this inflammation causes recurrent
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationAss. Prof. Pulmonary and Crit.Care Medical School,University of Athens
Diagnosis i of Exercise Induced Asthma Ch. Gratziou Ass. Prof. Pulmonary and Crit.Care Medical School,University of Athens Other Diagnostic Challenges for Exercise Induced Asthma Do we need other tests
More informationPulmonary function response to EDTA, an additive in nebulized bronchodilators
Pulmonary function response to EDTA, an additive in nebulized bronchodilators Michael J. Asmus, PharmD, a M. Dulce Barros, PhD, a Judy Liang, PharmD, a Sarah E. Chesrown, MD, PhD, b and Leslie Hendeles,
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationLong- and short-acting β 2 adrenoceptor agonists: interactions in human contracted bronchi
Eur Respir J 1998; 11: 583 588 DOI: 1.1183/931936.98.113583 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1998 European Respiratory Journal ISSN 93-1936 Long- and short-acting β 2 adrenoceptor
More informationEffect of inhaled budesonide therapy on lung function in schoolchildren born preterm
RESPIRATORY MEDICINE (2001) 95, 565 570 doi:10.1053/rmed.2001.1104, available online at http://www.idealibrary.com on Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm
More informationClinical equivalence of a novel nonchlorofluorocarbon-containing
Clinical equivalence of a novel nonchlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma Robert Dockhorn, MD," Jennifer
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationClinical Indications. Clinical Indications. RSPT 2317 Methylxanthines. RSPT 2317 Methylxanthines
RSPT 2317 Clinical Indications Theophylline management of asthma and COPD treatment of apnea of prematurity (AOP) diuretic (obsolete use) classified as a bronchodilator, but is weaker than β agonists effects
More informationLow- and high-dose fluticasone propionate in asthma; effects during and after treatment
Eur Respir J 2000; 15: 11±18 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2000 European Respiratory Journal ISSN 0903-1936 Low- and high-dose fluticasone propionate in asthma; effects
More informationL. Prieto*, J.M. Bertó*, V. Gutiérrez*, C. Tornero**
Eur Respir J, 1994, 7, 1845 1851 DOI:.1183/931936.94.71845 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1994 European Respiratory Journal ISSN 93-1936 Effect of inhaled budesonide on
More informationSOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS
SOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS Scott Haughie, M.Sc., Senior Director, Biostatistics IPAC-RS/UF Orlando Inhalation
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationClinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children
Eur Respir J 1998; 11: 35 354 DOI: 1.1183/931936.98.11235 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1998 European Respiratory Journal ISSN 93-1936 Clinical effect of Diskus dry-powder
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationASTHMA PROTOCOL CELLO
ASTHMA PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives, non medical and medical therapy and a scheme for inhaler dosage.
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationCystic fibrosis, atopy, and airways lability
Archives of Disease in Childhood, 1978, 53, 873-877 Cystic fibrosis, atopy, and airways lability M. SILVERMAN, F. D. R. HOBBS, I. R. S. GORDON, AND F. CARSWELL From the Departments of Child Health and
More information